“…CBA/CaJ (H-2 k ) or BALB/cByJ (H-2 d ) donors depending on availability were used for heterotopic cardiac transplantation (13,14) into C57BL (H-2 b ) recipients that were either wild-type (CBA to C57BL/6J, n ϭ 11; BALB/c to C57BL/6J, n ϭ 8) or had targeted gene disruption in IFN-␥ (C57BL/6J, n ϭ 10) (15), IL-4 (C57BL/6J, n ϭ 10) (16), or IL-10 (C57BL/10j, n ϭ 10) (17). Isograft controls included IFN-␥ Ϫ / Ϫ ( n ϭ 7), IL-4 Ϫ / Ϫ ( n ϭ 6), and IL-10 Ϫ / Ϫ ( n ϭ 5).…”